查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1808945

神经痛治疗市场，依治疗、最终用途、国家及地区 - 2025 年至 2032 年全球产业分析、市场规模、市场占有率及预测

Neuralgia Treatment Market, By Treatment, By End Use, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年神经痛治疗市场规模价值 26.9591 亿美元，2025 年至 2032 年的复合年增长率为 7.20%。

神经痛治疗是指治疗因损伤、感染或其他疾病引起的慢性神经疼痛的一种疾病。神经痛治疗旨在缓解症状、减缓病情进展并避免併发症。

神经痛治疗市场-市场动态

慢性病盛行率不断上升推动市场成长

糖尿病等慢性疾病的日益普及预计将推动神经痛治疗市场的未来成长。慢性疾病是指持续一年或更长时间，需要持续医疗照护、限制日常活动或两者兼而有之的疾病。糖尿病是一种以高血糖（也称为血糖）为特征的慢性代谢性疾病。神经痛治疗有助于治疗糖尿病神经病变，这是一种可能发生在糖尿病患者身上的神经损伤。例如，设在瑞士的联合国专门机构世界卫生组织报告称，2023年9月全球死亡人数为4,100万人，占全球非传染性疾病（NCD）或慢性疾病导致的死亡总数的74%。因此，糖尿病等慢性疾病的日益普及正在推动神经痛治疗市场的成长。

神经痛治疗市场-关键见解

根据我们的研究分析师的分析，预计全球市场在预测期内（2025-2032 年）的年复合成长率约为 7.20%。

根据治疗细分，预计 2025 年手术的市场份额将达到最高。

根据最终用途细分，2025 年最常见的最终用途将是医院和诊所。

2025 年，北美将成为收入最高的地区。

神经痛治疗市场-細項分析：

全球神经痛治疗市场根据治疗、最终用途和地区进行细分。

根据治疗方法，市场分为两类：药物治疗和手术治疗。到2025年，手术治疗将占据市场主导地位。对精准、非侵入性治疗方案（例如机器人放射外科手术）日益增长的需求是该领域的主要驱动力。这些先进的方法可以有针对性地缓解疼痛，同时减少对传统药物或侵入性手术的需求。机器人放射外科手术不仅精度高，而且对周围组织的损伤最小，进而改善患者的治疗效果。随着患者寻求更安全、更有效的治疗方案，市场正受到向微创治疗转变的推动。

根据最终用途，市场分为三类：医院和诊所、门诊手术中心和其他。到2025年，医院和诊所将占据最大的市场收入份额。医院和诊所采用先进的非侵入性技术，可实现更精准、更有针对性的治疗，进而推动市场成长。这些技术减少了对侵入性手术的需求，从而缩短了復原时间，减轻了患者的不适感。医疗保健提供者可以更精准地获得更好的治疗效果，从而提高患者的整体满意度。这种向微创治疗方案的转变增加了对先进神经痛治疗的需求。

神经痛治疗市场-地理洞察

由于糖尿病患者中糖尿病性疼痛性神经病变 (PDN) 等慢性疼痛疾病的盛行率不断上升，推动了对非侵入性有效治疗的需求，北美神经痛治疗市场将在 2025 年占据最大份额。美国食品药物管理局 (FDA) 于 2024 年 1 月批准了 Neuralace Medical 的非侵入性 Axon 疗法，用于治疗糖尿病性疼痛性神经病变。这项批准将推动糖尿病患者肢体神经痛的疼痛管理。 Axon 疗法透过低压电脉衝刺激神经，无需药物或手术即可减轻疼痛。该疗法更安全、更便捷，可望帮助许多患有慢性神经性疼痛的糖尿病患者。

亚太地区神经痛治疗市场将在预测期内成长最快。监管机构批准的创新治疗方案增加了该地区神经修復手术的选择。再生医学公司Orthocell Ltd.已获得新加坡卫生科学局（HSA）的Remplir监管批准，允许其于2025年第一季开始销售。知名医疗器材供应商Device Technologies在获得批准之前已在澳洲和纽西兰分销Remplir。 Remplir胶原蛋白包覆疗法可改善神经修復手术。

神经痛治疗市场-竞争格局：

神经痛治疗市场竞争适中，辉瑞、葛兰素史克、诺华和百健在抗惊厥药、抗忧郁药和局部止痛药领域占据主导地位。市场正在见证更多合作与併购，例如Globus Medical收购Nevro，以扩大其神经调节产品线。随着医疗服务可近性的改善和治疗费用的降低，亚太地区的区域性参与者也不断成长。总体而言，标靶药物疗法、微创疼痛管理解决方案以及个人化治疗方法的日益普及正在塑造神经痛治疗市场格局。

最新动态：

2024年1月，Zydus Lifesciences公司获得FDA最终批准，其仿製药加巴喷丁片可用于治疗带状疱疹后神经痛(PHN)。此核准涵盖了用于缓解带状疱疹后疼痛的药物，剂量分别为300毫克和600毫克，每日一次。

目录

第一章：神经痛治疗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 神经痛治疗市场片段（按治疗）
    • 神经痛治疗市场片段（依最终用途）
    • 神经痛治疗市场（按国家/地区）
    • 神经痛治疗市场（按地区）
  • 竞争洞察

第三章：神经痛治疗主要市场趋势

  • 神经痛治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 神经痛治疗市场的限制
    • 市场限制的影响分析
  • 神经痛治疗市场机会
  • 神经痛治疗市场未来趋势

第四章：神经痛治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：神经痛治疗市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：神经痛治疗市场格局

  • 2024年神经痛治疗市占分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：神经痛治疗市场－依治疗类型

  • 概述
    • 按治疗方式分類的细分市场占有率分析
    • 基于药物
      • 抗惊厥药物
      • 三环抗忧郁药
    • 手术
      • 射频热损伤
      • 立体定位放射外科
      • 显微血管减压术
      • 其他的

第 8 章：神经痛治疗市场 - 依最终用途

  • 概述
    • 按最终用途分類的细分市场份额分析
    • 医院和诊所
    • 门诊手术中心
    • 其他的

第九章：神经痛治疗市场－按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美神经痛治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按治疗类型）
    • 北美市场规模和预测，按最终用途
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲神经痛治疗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（按治疗类型）
    • 欧洲市场规模和预测，按最终用途
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区神经痛治疗主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依治疗类型）
    • 亚太地区市场规模及预测（依最终用途）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲神经痛治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依治疗类型）
    • 拉丁美洲市场规模及预测（依最终用途）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲神经痛治疗主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（以处理方式）
    • MEA 市场规模及预测（依最终用途）
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 10 章：神经痛治疗产业主要供应商分析

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • GSK plc.
    • Pfizer Inc.
    • Biogen
    • Zydus Group (Cadila Healthcare Limited)
    • H. Lundbeck A/S
    • Novartis AG
    • Others

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5576

Neuralgia Treatment Market size was valued at US$ 2,695.91 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

Neuralgia treatment is the treatment of a medical condition characterized by chronic pain in the nerves that can be caused by injury, infection, or other medical issues. Neuralgia treatment is used to alleviate symptoms, slow the progression of the condition, and avoid complications.

Neuralgia Treatment Market- Market Dynamics

Growing Prevalence Of Chronic Diseases Fuels Market Growth

The increasing prevalence of chronic diseases, such as diabetes, is expected to drive future growth in the neuralgia treatment market. Chronic diseases are problems that last a year or more and require ongoing medical care, limit daily activities, or both. Diabetes is a chronic metabolic condition characterized by high blood glucose, also known as blood sugar. Neuralgia treatment can help with diabetic neuropathy, which is nerve damage that can occur in people with diabetes. For instance, the World Health Organization, a United Nations specialized agency based in Switzerland, reported 41 million deaths in September 2023, accounting for 74% of all deaths caused by noncommunicable diseases (NCDs) or chronic diseases worldwide.As a result, the increasing prevalence of chronic diseases such as diabetes is driving the growth of the neuralgia treatment market.

Neuralgia Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)

According to treatment segmentation, the year 2025 is expected to see the highest market share for surgery.

According to End Use segmentation, the most common End Use in 2025 will be hospitals and clinics.

North America ranked as the top revenue-generating region in 2025.

Neuralgia Treatment Market- Segmentation Analysis:

The Global Neuralgia Treatment Market is segmented on the basis of Treatment, End Use, and Region.

The market is divided into two categories based on Treatment: Drug Based, and Surgery. The surgery segment will dominate the market in 2025. The growing demand for precise, non-invasive treatment options, such as robotic radiosurgery, is a major driver in the segment. These advanced methods provide targeted pain relief while reducing the need for traditional medications or invasive surgeries. Robotic radiosurgery allows for high accuracy while causing minimal damage to surrounding tissues, which improves patient outcomes. The market is being driven by a shift toward less invasive treatments, as patients seek safer, more effective alternatives.

The market is divided into three categories based on End Use: Hospital & Clinics, Ambulatory Surgery Centers, and Others. In 2025, the hospital and clinics segment will account for the largest market revenue share. Adoption of advanced, non-invasive technologies in hospitals and clinics drives market growth by allowing for more precise and targeted treatments. These technologies reduce the need for invasive procedures, resulting in faster recovery times and less patient discomfort. Healthcare providers can achieve better results with greater precision, increasing overall patient satisfaction. This shift toward less invasive options increases demand for advanced neuralgia treatments.

Neuralgia Treatment Market- Geographical Insights

North America neuralgia treatment market will hold the largest share in 2025 due to the rising prevalence of chronic pain conditions like painful diabetic neuropathy (PDN) among diabetics, driving demand for non-invasive, effective treatments. The FDA approved Neuralace Medical's non-invasive Axon Therapy for painful diabetic neuropathy in January 2024. This approval advances pain management for diabetics with limb nerve pain. Axon Therapy stimulates nerves with low-voltage electrical pulses to reduce pain without drugs or surgery. The therapy may help many diabetics with chronic neuropathic pain by being safer and more accessible.

Asia Pacific neuralgia treatment market to grow fastest over forecast period. Innovative treatment solutions approved by regulators have increased nerve repair surgery options in the region. Orthocell Ltd., a regenerative medicine company, received regulatory approval from Singapore's Health Sciences Authority (HSA) for Remplir, allowing sales to begin in Q1 of CY25. Device Technologies, a well-known medical device supplier, distributed Remplir in Australia and New Zealand before this approval. Remplir collagen wraps improve nerve repair surgery.

Neuralgia Treatment Market- Competitive Landscape:

The Neuralgia Treatment Market is moderately competitive, with Pfizer, GlaxoSmithKline, Novartis, and Biogen dominating the pharmaceutical segment with anticonvulsants, antidepressants, and topical analgesics. The market is seeing more collaboration and mergers, such as Globus Medical's acquisition of Nevro, to expand its neuromodulation offerings. Regional players in Asia-Pacific are also gaining ground as healthcare access improves and therapies become more affordable. Overall, the landscape is shaped by advances in targeted drug therapies, minimally invasive pain management solutions, and the growing use of personalized treatment approaches.

Recent Developments:

In January 2024, Zydus Lifesciences has received final FDA approval for its generic Gabapentin tablets for the treatment of postherpetic neuralgia (PHN). The approval covers 300 mg and 600 mg once-daily doses of a drug used to relieve pain after shingles.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEURALGIA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • GSK plc.
  • Pfizer Inc.
  • Biogen
  • Zydus Group (Cadila Healthcare Limited)
  • H. Lundbeck A/S
  • Novartis AG
  • Others

GLOBAL NEURALGIA TREATMENT MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Drug Based
  • Anticonvulsant Medicines
  • Tricyclic Antidepressants
  • Surgery
  • Radiofrequency Thermal Lesioning
  • Stereotactic Radiosurgery
  • Microvascular Decompression
  • Others

GLOBAL NEURALGIA TREATMENT MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032

  • Hospital & Clinics
  • Ambulatory Surgery Centers
  • Others

GLOBAL NEURALGIA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuralgia Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuralgia Treatment Market Snippet by Treatment
    • 2.1.2. Neuralgia Treatment Market Snippet by End Use
    • 2.1.3. Neuralgia Treatment Market Snippet by Country
    • 2.1.4. Neuralgia Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuralgia Treatment Key Market Trends

  • 3.1. Neuralgia Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuralgia Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuralgia Treatment Market Opportunities
  • 3.4. Neuralgia Treatment Market Future Trends

4. Neuralgia Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuralgia Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Neuralgia Treatment Market Landscape

  • 6.1. Neuralgia Treatment Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuralgia Treatment Market - By Treatment

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
    • 7.1.2. Drug Based
      • 7.1.2.1. Anticonvulsant Medicines
      • 7.1.2.2. Tricyclic Antidepressants
    • 7.1.3. Surgery
      • 7.1.3.1. Radiofrequency Thermal Lesioning
      • 7.1.3.2. Stereotactic Radiosurgery
      • 7.1.3.3. Microvascular Decompression
      • 7.1.3.4. Others

8. Neuralgia Treatment Market - By End Use

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End Use, 2024 & 2032 (%)
    • 8.1.2. Hospital & Clinics
    • 8.1.3. Ambulatory Surgery Centers
    • 8.1.4. Others

9. Neuralgia Treatment Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Neuralgia Treatment Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Neuralgia Treatment Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.3.7. UK
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.3.7.4. UK Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.3.8. France
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.3.8.4. France Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.3.9. Italy
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.3.9.4. Italy Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.3.10. Spain
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.3. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.3.10.4. Spain Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.3.11. The Netherlands
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.3. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.3.11.4. The Netherlands Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Overview
      • 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.3.12.4. Sweden Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.3.13. Russia
      • 9.3.13.1. Overview
      • 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.3.13.4. Russia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.3.14. Poland
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Poland Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.3.15. Rest of Europe
      • 9.3.15.1. Overview
      • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.15.3. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.3.15.4. Rest of the Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Neuralgia Treatment Key Manufacturers in Asia Pacific
    • 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 9.4.5. APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.4.6. China
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.4.6.4. China Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.4.7. India
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.4.7.4. India Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.4.11. Indonesia
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Indonesia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.4.12. Thailand
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Thailand Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  • 9.5. Latin America (LATAM)
    • 9.5.1. Overview
    • 9.5.2. Neuralgia Treatment Key Manufacturers in Latin America
    • 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 9.5.5. LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa (MEA)
    • 9.6.1. Overview
    • 9.6.2. Neuralgia Treatment Key Manufacturers in Middle East and Africa
    • 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 9.6.5. MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.6.7. UAE
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. UAE Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.6.7.4. UAE Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Neuralgia Treatment Industry

  • 10.1. Competitive Benchmarking
    • 10.1.1. Competitive Dashboard
    • 10.1.2. Competitive Positioning
  • 10.2. Company Profiles
    • 10.2.1. GSK plc.
    • 10.2.2. Pfizer Inc.
    • 10.2.3. Biogen
    • 10.2.4. Zydus Group (Cadila Healthcare Limited)
    • 10.2.5. H. Lundbeck A/S
    • 10.2.6. Novartis AG
    • 10.2.7. Others

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us